Quantcast
Last updated on April 23, 2014 at 12:08 EDT

Latest Pre-exposure prophylaxis Stories

2011-05-18 08:14:00

Argues AIDS vaccine research is a key part of the HIV prevention revolution NEW YORK, May 18, 2011 /PRNewswire-USNewswire/ -- This year HIV Vaccine Awareness Day comes at the dawn of a true prevention revolution that could finally turn the tide of the AIDS epidemic. AIDS vaccine research is a critical part of that revolution and on this day AVAC calls on donors, policy makers and others to strengthen support for AIDS vaccine research. "This is an exciting time in HIV prevention...

2011-03-14 15:05:27

The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis (PrEP) can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/apc After the...

2011-02-28 14:14:46

Preferences for HIV prevention products differ among US and African women In the first study to make head-to-head comparisons between tenofovir gel and oral tenofovir "“ two promising approaches for preventing HIV in women "“ researchers found that daily use of the vaginal gel achieved a more than 100-times higher concentration of active drug in vaginal tissue than did the oral tablet, while, compared to the gel, the tablet used daily was associated with a 20-times higher active...

2011-02-28 14:11:40

Strongest effect seen in tissue taken from participants after 1 week of use A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel...

2010-12-23 12:56:00

WASHINGTON, Dec. 23, 2010 /PRNewswire-USNewswire/ -- On December 17, Science Magazine recognized a promising HIV study as one of the top ten achievements of 2010. The groundbreaking research provided the first-ever proof of concept that a microbicide can effectively and safely reduce HIV transmission in women. Ninety percent of the study was funded by USAID as part of the U.S. President's Emergency Plan for AIDS Relief. (Logo: http://photos.prnewswire.com/prnh/20091022/USAIDLOGO) The...

2010-12-01 06:00:00

SEATTLE, Dec. 1, 2010 /PRNewswire-USNewswire/ -- World AIDS Day 2010 comes at a time of renewed hope in the HIV prevention field. In the past 15 months, scientific research has delivered exciting results in the fight against HIV. A vaccine study in Thailand, a microbicide study in South Africa and a multi-country study on the use of HIV drugs to prevent infection have all demonstrated a level of efficacy that brings new hope for the prevention of HIV. Unfortunately, many of these...

2010-11-23 13:28:42

Successful trial provides proof of concept for oral use of antiretrovirals in preventing HIV infections in men who have sex with men CONRAD is pleased to join in congratulating the Global iPrEx study team for their successful trial of oral tenofovir (TDF) with emtricitabine (FTC) for HIV prevention. Results of the National Institutes of Health (NIH) sponsored study were announced today in the New England Journal of Medicine. Daily use of the widely used antiretroviral combination pill was...

2010-11-23 13:25:54

Major study published in the New England Journal of Medicine demonstrates the effectiveness of a new HIV prevention tool, pre-exposure prophylaxis (PrEP) In a finding with the potential to fundamentally change strategies to slow the global HIV epidemic, a new study called iPrEx shows that individuals at high risk for HIV infection who took a single daily tablet containing two widely used HIV medications, emtricitabine and tenofovir (FTC/TDF), experienced an average of 43.8% fewer HIV...

2010-11-23 13:00:23

NIH's NIAID-sponsored Study Finds Pre-exposure Prophylaxis Concept Effective Among Men who Have Sex with Men A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. The findings, a major advance in HIV prevention research, come from a large international clinical trial published online Nov. 23 by the New England Journal of Medicine. The study, titled "Chemoprophylaxis...

2010-11-23 12:49:18

The results of the iPrEx PrEP effectiveness trial of once-daily TDF/FTC (brand name Truvada) in gay men, transgender women and other men who have sex with men are a landmark in HIV prevention research. The results, released on November 23, showed that TDF/FTC reduced risk of HIV infection by an average of 43.8%. This was calculated by looking at rates of infections among participants who received TDF/FTC plus a standard prevention package compared to those in the placebo arm who received a...